Anticoagulation Management for Patients with Mechanical Heart Valves

Introduction to Bridging Anticoagulation

The American College of Cardiology recommends bridging anticoagulation with therapeutic-dose low molecular weight heparin (LMWH) for patients with mechanical heart valves requiring surgery when the international normalized ratio (INR) falls below the therapeutic threshold (2.0-2.5), typically 36-48 hours before surgery, and stopped 12 hours before the procedure 1
Bridging therapy should be based on thromboembolism risk, including factors such as mechanical mitral valve replacement, older-generation mechanical valve, multiple mechanical valves, and additional risk factors like atrial fibrillation, previous thromboembolism, hypercoagulable condition, or left ventricular dysfunction 1
Bileaflet mechanical aortic valve without additional risk factors may not require bridging therapy, as recommended by the American College of Cardiology 1

Stop warfarin 3-4 days before the procedure to allow INR to fall below 1.5 for major surgical procedures, and start LMWH when INR falls below therapeutic threshold (2.0-2.5) with a dosage of 1 mg/kg subcutaneously twice daily for high-risk patients, beginning approximately 36-48 hours before surgery 1
Resume warfarin 12-24 hours postoperatively once hemostasis is achieved, as recommended by the American Heart Association 2
Resume LMWH based on bleeding risk, with low bleeding risk procedures resuming full-dose LMWH 24 hours after procedure, and high bleeding risk procedures delaying resumption of LMWH for 48-72 hours or considering prophylactic dosing initially 1
Continue LMWH until INR returns to therapeutic range (≥2.0) 1

Monitor INR regularly during the bridging period, and consider anti-Xa monitoring in high-risk cases on LMWH 3, 1
Bridging with LMWH is associated with low rates of thromboembolic events (0.4-0.9%) in mechanical valve patients, but increases bleeding risk compared to no bridging, with a strength of evidence based primarily on observational studies rather than randomized controlled trials (RCTs) 1
Inadequate monitoring, inappropriate timing, renal impairment, and delayed resumption of anticoagulation can lead to increased bleeding or thromboembolism risk, highlighting the need for careful management and individualized treatment plans 1, 2

For patients requiring emergency surgery while on warfarin, consider fresh frozen plasma or prothrombin complex concentrate to rapidly reverse anticoagulation, as recommended by the American College of Cardiology 1
The decision to bridge should carefully balance thromboembolism and bleeding risks, with bridging generally recommended for high-risk mechanical valve patients, including those with mechanical mitral valve replacement, older-generation mechanical valves, recent thromboembolic event, multiple mechanical valves, or mechanical valve plus additional risk factors 1, 2
High-risk patients with mechanical heart valves should receive therapeutic-dose LMWH, with dosing adjusted for renal impairment to avoid accumulation and bleeding, and anticoagulation resumed based on bleeding risk, with low bleeding risk patients resuming therapeutic-dose anticoagulation 24 hours after procedure, and high bleeding risk patients considering delayed resumption or reduced-dose regimen initially 1, 3